Aspira Women's Health, Inc. (AWH) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Spero Therapeutics, Inc.

HCW Biologics Inc.

Shattuck Labs, Inc.

Enzo Biochem, Inc.

Aspira Women's Health, Inc.

Avrobio, Inc.

Elicio Therapeutics, Inc.

Nkarta, Inc.

CEL-SCI Corp.

Intensity Therapeutics, Inc.

Syros Pharmaceuticals, Inc.

Why is Aspira Women's Health, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate 6.07% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -23.15

The company has declared negative results in Mar'2026 after 5 consecutive positive quarters

INTEREST(HY) At USD 0.23 MM has Grown at 759.26%
RAW MATERIAL COST(Y) Grown by 20.76% (YoY)
CASH AND EQV(HY) Lowest at USD 3.1 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 185.71%, its profits have risen by 65.9%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Aspira Women's Health, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Aspira Women's Health, Inc.

185.71%

-0.52

165.80%

S&P 500

22.24%

1.91

13.23%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

15.67%

EBIT Growth (5y)

6.07%

EBIT to Interest (avg)

-23.15

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

1.41

Sales to Capital Employed (avg)

0.06

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

4.70%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-3.50

EV to EBIT

-1.28

EV to EBITDA

-1.30

EV to Capital Employed

-1.95

EV to Sales

1.38

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Sideways

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -4.28 MM

NET PROFIT(HY)

Higher at USD -4.21 MM

DEBT-EQUITY RATIO (HY)

Lowest at -47 %

EPS(Q)

Highest at USD -0.05

-23What is not working for the Company

INTEREST(HY)

At USD 0.23 MM has Grown at 759.26%

RAW MATERIAL COST(Y)

Grown by 20.76% (YoY

CASH AND EQV(HY)

Lowest at USD 3.1 MM

NET SALES(Q)

Lowest at USD 1.97 MM

PRE-TAX PROFIT(Q)

Lowest at USD -2.43 MM

NET PROFIT(Q)

Lowest at USD -2.43 MM

Here's what is working for Aspira Women's Health, Inc.

Operating Cash Flow

Highest at USD -4.28 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

EPS

Highest at USD -0.05

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debt-Equity Ratio

Lowest at -47 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Aspira Women's Health, Inc.

Interest

At USD 0.23 MM has Grown at 759.26%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Pre-Tax Profit

At USD -2.43 MM has Fallen at -58.44%

over average net sales of the previous four periods of USD -1.54 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -2.43 MM has Fallen at -58.44%

over average net sales of the previous four periods of USD -1.54 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Net Sales

At USD 1.97 MM has Fallen at -14.63%

over average net sales of the previous four periods of USD 2.3 MM

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Net Sales

Lowest at USD 1.97 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Pre-Tax Profit

Lowest at USD -2.43 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Lowest at USD -2.43 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Cash and Eqv

Lowest at USD 3.1 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 20.76% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales